**Introduction**

In an effort to reduce national re/excision rates, in 2014 the Society of Surgical Oncology and the American Society for Radiation Oncology announced a Consensus Guideline of “No Ink on Tumor” to define adequate margins for patients with early stage invasive cancer undergoing breast-conserving surgery (BCS) and whole-breast radiation.\(^1\)

Post Consensus Guideline adoption, our re-excision rate was 12.7%. We sought to determine if utilizing MarginProbe Radiofrequency Spectroscopy could further reduce positive margin and subsequent re-excision rate, without increasing excised tissue volume, in the "No Ink on Tumor" era.

**Materials and Methods**

The MarginProbe Radiofrequency Spectroscopy System (Fig 1) captures the bioelectric signature of tissue at the surface of the lumpectomy specimen, characterizing it as benign or malignant, in real time.

![MarginProbe System](https://via.placeholder.com/150)

**Figure 1 - MarginProbe System**

We present a retrospective observational review of 237 consecutive cases from Jan, 2016 - Apr, 2018, representing the 150 consecutive patients directly before, and 87 consecutive patients directly after implementation of MarginProbe for intraoperative margin assessment.

All patients were newly diagnosed with invasive cancer or DCIS, scheduled for Breast Conserving Therapy, and received standard of care comprised of image guided localization, intraoperative x-ray specimen imaging, and intraoperative margin color inking for orientation. (Table 1)

**Results**

Utilization of MarginProbe produced a statistically significant relative reduction in re-excision of 73.2%, from the historical incidence of 12.7% (19/150) to 3.4% (3/87) in the device arm, with a P-value of 0.0197. (Table 2)

<table>
<thead>
<tr>
<th>Historical Control</th>
<th>MarginProbe</th>
<th>Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumpectomies</td>
<td>150</td>
<td>87</td>
</tr>
<tr>
<td>Re-excisions</td>
<td>19</td>
<td>3</td>
</tr>
<tr>
<td>Re-excision Rate</td>
<td>12.7%</td>
<td>3.4%</td>
</tr>
</tbody>
</table>

We found that implementing MarginProbe for directed shaves. Importantly, malignant disease which would have been previously unknown, can be identified and removed utilizing MarginProbe for directed shaves.

**Discussion**

The 2014 Consensus Guideline of "No Ink on Tumor" to define adequate invasive margin seeks to reduce national re/excision rates and reduce cost to the healthcare system while improving quality of care and patient satisfaction.

Multiple studies to date report the Guideline impact on re-excision for invasive cancer to be a relative reduction of 8-33%, resulting in re-excision rates of 11-21%. A recent meta-analysis on Guideline impact reports a 35% odds reduction, with re-excision prevalence decreasing from 22 to 14.\(^8\)

We found that implementing MarginProbe as an adjunct to standard of care post consensus guideline significantly reduced re-excisions to the low single digits for breast cancer across all subgroups while decreasing total volume of tissue removed.

Importantly, malignant disease which would have been previously unknown, can be identified and removed utilizing MarginProbe for directed shaves.

Future studies should seek to determine if this identification and removal of residual disease will have a positive effect on lowering recurrence rates.

**References**


Rhonda Wachsmuth, MD FACS: Georgia Breast Care, Marietta, GA

---

**Table 1 – Patient Characteristics**

<table>
<thead>
<tr>
<th>Age mean (range)</th>
<th>65 (41-88)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor size mean (range)</td>
<td>1.5 (0-6.4) cm</td>
</tr>
<tr>
<td>Tumor Histology</td>
<td>IDC 73% (109/150), ILC 11% (17/150), DCIS 16% (24/150)</td>
</tr>
<tr>
<td>DCIS Component</td>
<td>45% (67/150)</td>
</tr>
</tbody>
</table>

**Table 2 – Reduction in re-excision vs historical control**

<table>
<thead>
<tr>
<th>Total</th>
<th>150</th>
<th>19</th>
<th>12.7%</th>
<th>87</th>
<th>3</th>
<th>3.4%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumpectomies</td>
<td>Re-excisions</td>
<td>Re-excision Rate</td>
<td>Lumpectomies</td>
<td>Re-excisions</td>
<td>Re-excision Rate</td>
<td>Relative Reduction</td>
</tr>
<tr>
<td>-------</td>
<td>-----</td>
<td>----</td>
<td>-------</td>
<td>----</td>
<td>---</td>
<td>-----</td>
</tr>
<tr>
<td>63%</td>
<td>84%</td>
<td>0.0197</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 3 – Tissue Volume**

- **Historical Tissue Volume** 69.2cc
- **Device Tissue Volume** 55.9cc

---

**Discussion**

The 2014 Consensus Guideline of "No Ink on Tumor" to define adequate invasive margin seeks to reduce national re/excision rates and reduce cost to the healthcare system while improving quality of care and patient satisfaction.

Multiple studies to date report the Guideline impact on re-excision for invasive cancer to be a relative reduction of 8-33%, resulting in re-excision rates of 11-21%. A recent meta-analysis on Guideline impact reports a 35% odds reduction, with re-excision prevalence decreasing from 22 to 14.

We found that implementing MarginProbe as an adjunct to standard of care post consensus guideline significantly reduced re-excisions to the low single digits for breast cancer across all subgroups while decreasing total volume of tissue removed.

Importantly, malignant disease which would have been previously unknown, can be identified and removed utilizing MarginProbe for directed shaves.

Future studies should seek to determine if this identification and removal of residual disease will have a positive effect on lowering recurrence rates.

**References**